Barely three years since its coronavirus vaccine helped stem the pandemic, Pfizer’s stock has lost 50 percent of its value ...

The activist investment firm Starboard Value has launched a proxy fight again Pfizer, questioning the company’s management ...

The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...

Activist investor Starboard Value claims the pharma giant’s former CEO and CFO were “threatened” into backing current ...

All the companies have skin in the game for clotting/bleeding disorders. The BMS-Pfizer Alliance market Factor Xa blood ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...

Pfizer's Hympavzi receives FDA approval as the first anti-TFPI therapy for hemophilia A and B. This subcutaneous, once-weekly ...

Starboard Value alleged that Pfizer officials threatened legal action against two former top executives who had been working ...

The corporate clash between Pfizer and Starboard Value heated up on Thursday when the activist investment firm pressed the ...

On Oct. 6, The Wall Street Journal reported that activist investor group Starboard Value owns a stake in Pfizer ( PFE -0.61%) ...

Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...